Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BEBT-706
- Development stage
- Preclinical
- Lead developer
- BeBetter Med
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
BEBT-706 is a dual-target small interfering RNA (siRNA) therapeutic being developed by Guangzhuo BeBetter Medicine Technology. It is designed to simultaneously target Lipoprotein(a) [Lp(a)] and Proprotein convertase subtilisin/kexin type 9 (PCSK9) using the company's proprietary GDOC (dual-target siRNA) platform. By silencing the expression of these two key drivers of cardiovascular risk, BEBT-706 aims to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). The drug is currently in the preclinical stage of development.
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)LPA (Lysophosphatidic acid)
Beyond the preview
Go deeper on BEBT-706.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BEBT-706.